GRANULES896.50

Granules India Ltd.

· Pharma & Health
₹ CrorePeersAUROPHARMAIPCALABAARTIDRUGSERISINDGNEMCUREJUBLPHARMACONCORDBIOMcap ₹22,215 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)214.97284.14290.82290.82
Receivable Days (DSO)79.8576.7461.8661.86
Payable Days (DPO)123.89153.64116.95113.32
Cash Conversion Cycle (days)170.93207.24235.73239.36
Working Capital Turnover5.484.033.203.36
Asset Turnover0.820.720.700.70
Cash Conversion (CFO/Net Income)1.081.731.331.33
CFO/EBITDA0.510.920.670.67
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.